NCT03740945View on ClinicalTrials.gov

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 6, 2018

Primary Completion Date

December 5, 2019

Study Completion Date

December 5, 2019

Conditions
Vaginal Atrophy in Breast Cancer Patients
Interventions
DRUG

Placebo

Daily administration of one placebo vaginal ovule at bedtime

DRUG

Prasterone (DHEA)

Daily administration of one prasterone vaginal ovule at bedtime

Sponsors

Lead Sponsor

EndoCeutics Inc.
All Listed Sponsors
collaborator

AMAG Pharmaceuticals, Inc.

INDUSTRY

lead

EndoCeutics Inc.

INDUSTRY